Tower Research Capital LLC (Trc) Nektar Therapeutics Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Nektar Therapeutics stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 17,881 shares of NKTR stock, worth $16,271. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,881
Previous 9,220
93.94%
Holding current value
$16,271
Previous $11,000
109.09%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding NKTR
# of Institutions
145Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$14.5 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$13.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$11.9 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$8.55 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$8.37 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $171M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...